Regulus Therapeutics to Present at the Leerink Partners 2025 Global Healthcare Conference
Rhea-AI Summary
Regulus Therapeutics (Nasdaq: RGLS), a biopharmaceutical company specializing in microRNA-targeted medicine development, has announced its upcoming participation at the Leerink Partners 2025 Global Healthcare Conference. The company's management team will engage in a fireside chat scheduled for Tuesday, March 11th at 3:40 p.m. ET.
Investors and interested parties can access both the live presentation and its replay through the 'Events and Presentations' section on Regulus' investor relations website. The presentation recording will remain accessible for 90 days following the event.
Positive
- None.
Negative
- None.
News Market Reaction – RGLS
In the trading session that priced this news, RGLS gained 7.14%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
The live event and replay of the presentation will be available under "Events and Presentations" through the investor relations section of the Company's website at https://ir.regulusrx.com/events and archived for 90 days following the presentation date.
About Regulus
Regulus Therapeutics Inc. (Nasdaq: RGLS) is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a pipeline complemented by a rich intellectual property estate in the microRNA field. Regulus maintains its corporate headquarters in
View original content to download multimedia:https://www.prnewswire.com/news-releases/regulus-therapeutics-to-present-at-the-leerink-partners-2025-global-healthcare-conference-302390551.html
SOURCE Regulus Therapeutics Inc.